SSTR2 and neuroendocrine neoplasm: Furthermore, a Lu-177-labeled peptide-based radiopharmaceutical (Lu-177-dotatate) targeting somatostatin receptor 2, which is highly expressed in neuroendocrine tumors, was approved by the Food and Drug Administration [31].